4.6 Article

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance

Journal

BLOOD ADVANCES
Volume 2, Issue 14, Pages 1773-1783

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/bloodadvances.2018019620

Keywords

-

Categories

Funding

  1. Deutsche Jose Carreras Leukamie Stiftung [DJCLS R 15/02]
  2. Joseph Senker Stiftung
  3. Public Health Service [5U24-CA076518]
  4. National Institutes of Health National Cancer Institute
  5. National Institutes of Health National Heart, Lung and Blood Institute [5U10HL069294]
  6. Office of Naval Research [N00014-15-1-0848, N00014-16-1-2020]
  7. Alexion
  8. Amgen, Inc.
  9. Astellas Pharma US
  10. AstraZeneca
  11. Be the Match Foundation
  12. Bluebird Bio, Inc.
  13. Bristol Myers Squibb Oncology
  14. Celgene Corporation
  15. Cellular Dynamics International, Inc.
  16. Chimerix, Inc.
  17. Fred Hutchinson Cancer Research Center
  18. Gamida Cell Ltd.
  19. Genentech, Inc.
  20. Genzyme Corporation
  21. Gilead Sciences, Inc.
  22. Health Research, Inc. Roswell Park Cancer Institute
  23. HistoGenetics, Inc.
  24. Incyte Corporation
  25. Janssen Scientific Affairs, LLC
  26. Jazz Pharmaceuticals, Inc.
  27. Jeff Gordon Children's Foundation
  28. Leukemia AMP
  29. Lymphoma Society
  30. Medac, GmbH
  31. MedImmune
  32. Medical College of Wisconsin
  33. Merck Co., Inc.
  34. Mesoblast
  35. MesoScale Diagnostics, Inc.
  36. Miltenyi Biotec, Inc.
  37. National Marrow Donor Program
  38. Neovii Biotech NA, Inc.
  39. Novartis Pharmaceuticals Corporation
  40. Onyx Pharmaceuticals
  41. Optum Healthcare Solutions, Inc.
  42. Otsuka America Pharmaceutical, Inc.
  43. Otsuka Pharmaceutical Co, Ltd. - Japan
  44. PCORI
  45. Perkin Elmer, Inc.
  46. Pfizer, Inc
  47. Sanofi US
  48. Seattle Genetics
  49. Spectrum Pharmaceuticals, Inc.
  50. St. Baldrick's Foundation
  51. Sunesis Pharmaceuticals, Inc.
  52. Swedish Orphan Biovitrum, Inc.
  53. Takeda Oncology
  54. Telomere Diagnostics, Inc.
  55. University of Minnesota
  56. Wellpoint, Inc.
  57. National Cancer Institute [5U10HL069294]
  58. Health Resources and Services Administration (Department of Health and Human Services) [CHHSH250201200016C]
  59. National Institute of Allergy and Infectious Diseases
  60. National Heart, Lung and Blood Institute
  61. NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER
  62. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL069294] Funding Source: NIH RePORTER

Ask authors/readers for more resources

In silico prediction of high-risk donor-recipient HLA mismatches after unrelated donor (UD) hematopoietic cell transplantation (HCT) is an attractive, yet elusive, objective. Nonpermissive T-cell epitope (TCE) group mismatches were defined by alloreactive T-cell cross-reactivity for 52/80 HLA-DPB1 alleles (TCE-X). More recently, a numerical functional distance (FD) scoring system for in silico prediction of TCE groups based on the median impact of exon 2-encoded amino acid polymorphism on T-cell alloreactivity was developed for all DPB1 alleles (TCE-FD), including the 28/80 common alleles not assigned by TCE-X. We compared clinical outcome associations of nonpermissive DPB1 mismatches defined by TCE-X or TCE-FD in 8/8 HLA-matched UD-HCT for acute leukemia, myelodysplastic syndrome, and chronic myelogenous leukemia between 1999 and 2011 (N=2730). Concordance between the 2 models was 92.3%, with most differences arising from DPB1*06:01 and DPB1*19:01 being differently assigned by TCE-X and TCE-FD. In both models, nonpermissive mismatches were associated with reduced overall survival (hazard ratio [HR], 1.15, P<.006 and HR, 1.12, P<.03), increased transplant-related mortality (HR, 1.31, P<.001 and HR, 1.26, P<.001) as well as acute (HR, 1.16, P<.02 and HR, 1.22, P<.001) and chronic (HR, 1.20, P<.003 and HR, 1.22, P<.001) graft-versus-host disease (GVHD). We show that in silico prediction of nonpermissive DPB1 mismatches significantly associated with major transplant outcomes is feasible for any DPB1 allele with known exon 2 sequence based on experimentally elaborated FD scores. This proof-of-principle observation opens new avenues for developing HLA risk-prediction models in HCT and has practical implications for UD searches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available